Answers are grounded in this paper and cite their sources.
Network pharmacology reveals icariin modulates MAPK signaling in diabetic cognitive impairment, suggesting therapeutic potential.
Introduction: Neuroinflammation plays a pivotal role in diabetes-associated cognitive dysfunction. Icariin (ICA), a bioactive flavonoid from Epimedium, shows neuroprotective potential, though its mechanism remains unclear. Methods: Potential ICA targets and diabetic cognitive impairment-related genes were identified through database mining. A protein-protein interaction network was constructed (STRING database) and analyzed (Cytoscape) to identify hub genes. Molecular docking and dynamics simulations validated key targets, followed by in vitro validation using high glucose-induced HT22 cells. Results: Network pharmacology suggested ICA's neuroprotection involves MAPK pathway modulation and anti-inflammatory effects. In vitro studies confirmed ICA suppressed pro-inflammatory cytokine release and regulated MAPK signaling. Discussion: ICA's neuroprotection aligns with known flavonoid anti-inflammatory properties. However, limitations include single-cell line use and potentially non-physiological concentrations. Future studies should assess ICA in diabetic animal models, blood-brain barrier penetration, and synergy with antidiabetic drugs. Conclusion: ICA protects HT22 cells from high glucose-induced damage via MAPK signaling and reduces inflammation, suggesting therapeutic potential for diabetic cognitive impairment. Further in vivo validation is warranted.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: